Akero Therapeutics Inc (NASDAQ: AKRO) open the trading on Wednesday, with a bit cautious approach as it glided -0.39% to $53.6, before settling in for the price of $53.81 at the close. Taking a more long-term approach, AKRO posted a 52-week range of $21.34-$58.40.
It was noted that the giant of the Healthcare sector posted annual sales growth of -5.28% over the last 5 years. Meanwhile, its Annual Earning per share during the time was -5.28%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 0.47%. This publicly-traded company’s shares outstanding now amounts to $79.92 million, simultaneously with a float of $70.83 million. The organization now has a market capitalization sitting at $4.30 billion.
Akero Therapeutics Inc (AKRO) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Akero Therapeutics Inc’s current insider ownership accounts for 11.65%, in contrast to 108.68% institutional ownership. According to the most recent insider trade that took place on Oct 10 ’25, this organization’s President and CEO sold 30,000 shares at the rate of 53.98, making the entire transaction reach 1,619,340 in total value, affecting insider ownership by 526,114. Preceding that transaction, on Oct 07 ’25, Company’s Chief Scientific Officer sold 12,500 for 46.08, making the whole transaction’s value amount to 576,001. This particular insider is now the holder of 166,571 in total.
Akero Therapeutics Inc (AKRO) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.97 per share during the current fiscal year.
Akero Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 0.47% and is forecasted to reach -4.17 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -5.28% through the next 5 years, which can be compared against the -5.28% growth it accomplished over the previous five years trading on the market.
Akero Therapeutics Inc (NASDAQ: AKRO) Trading Performance Indicators
Let’s observe the current performance indicators for Akero Therapeutics Inc (AKRO). It’s Quick Ratio in the last reported quarter now stands at 12.66.
In the same vein, AKRO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.80, a figure that is expected to reach -0.93 in the next quarter, and analysts are predicting that it will be -4.17 at the market close of one year from today.
